Temi della conferenza With clinical holds lifting there has been more investment and clinical progress in the gene therapy for muscular disorders space than ever before, yet the consequences of toxicity are not a distant memory. Despite the successes, there are still withstanding challenges for gene therapy developers targeting the muscle when it comes to optimizing delivery and navigating toxicity to develop truly safe and transformative therapeutics for muscular disorders patients.
Speakers: Michael O'Callaghan, Senior Vice President, Translational Medicine, AskBio, Michael Roberts, Chief Technology Officer, AskBio Europe, and more.
